Development of novel antimicrobials has slowed, and the preclinical and clinical pipeline is likely to be insufficient to support current and future patient needs.
Prescription Drugs
Reports
Displaying 1 - 10 of 68. 10 per page. Page 1.
Advanced SearchFact Sheet
Inflation Reduction Act Research Series: Medicare Enrollees’ Use and Out-of-Pocket Expenditures for Drugs Selected for Negotiation under the Medicare Drug Price Negotiation Program
August 29, 2023
The Inflation Reduction Act (IRA) authorizes the Secretary of the Department of Health and Human Services (HHS) to negotiate prices directly with participating manufacturers for selected drugs that have high total spending and are high expenditure, single source drugs without generic or biosimilar competition.
Report
Analysis of Market Challenges for Antimicrobial Drug Development in the United States
August 28, 2023
The market for antimicrobial (AM) drugs is unique in that it is associated with a positive externality (public health) as well as a negative externality (antimicrobial resistance, or AMR) (Mossialos, et al., 2010). AMR occurs when microbes change over time and no longer respond to available medicine.
Report
Antimicrobial Drugs - Market Returns Analysis
August 28, 2023
In 2017, at least 2.8 million people in the U.S. acquired serious infections with bacteria that are resistant to one or more antimicrobial drugs and 35,000 have died as a result. Resistance to antimicrobials is viewed as a global threat with antimicrobial drug use in human and animal health driving resistance.
Report
The Inflation Reduction Act of 2022: One Year Anniversary Highlights from ASPE Drug Pricing Reports
August 16, 2023
Introduction
Report
Inflation Reduction Act Research Series: Medicare Part D Enrollee Out-of-Pocket Spending: Recent Trends and Projected Impacts of the Inflation Reduction Act
July 6, 2023
The Inflation Reduction Act (IRA) will make key changes to improve drug affordability for people who have Medicare.
Report to Congress
ASPE Report to Congress: Impact of Drug Shortages on Consumer Costs
May 22, 2023
Prescription drug shortages are an ongoing concern in the United States (U.S.). While prior analyses explore the frequency of drug shortages in the U.S., little is known about the extent to which U.S. shortages impact consumer costs and healthcare systems. Drug shortages impact consumer costs in various ways.
ASPE Issue Brief
FDA User Fees: Examining Changes in Medical Product Development and Economic Benefits
March 31, 2023
This issue brief provides a primer on FDA user fees, presents findings of how user fees affect the cost of medical product development, and summarizes the research literature on user fees, most notably in expediting medical product development and approval.
ASPE Issue Brief
Inflation Reduction Act Research Series: Medicare Part D Enrollee Savings from Elimination of Vaccine Cost-Sharing
March 15, 2023
Effective January 1, 2023, the Inflation Reduction Act (IRA) eliminated enrollee cost-sharing for recommended vaccines covered under Medicare Part D. In 2021, 3.4 million people received vaccines under Part D, and annual out-of-pocket costs were $234 million.
ASPE Issue Brief
COVID-19 Antivirals Utilization: Geographic and Demographic Patterns of Treatment in 2022
December 23, 2022
This report examines the utilization of oral antiviral medications, Paxlovid and Lagevrio, for the treatment of COVID-19. The analyses include an examination of time trends of COVID-19 antiviral use as well as breakdowns by age cohorts and gender. The report finds that utilization in the U.S.